Detailed Information

Cited 15 time in webofscience Cited 18 time in scopus
Metadata Downloads

Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Studyopen access

Authors
Choi, Chang HwanDo Song, InKim, Young-HoKoo, Ja SeolKim, You SunKim, Joo SungKim, NayoungKim, Eun SooKim, Jae HakKim, Ji WonKim, Tae OhKim, Hyun SooKim, Hyo JongPark, Young SookPark, Dong IlPark, Soo JungSong, Hyun JooShin, Sung JaeYang, Suk-KyunYe, Byong DukLee, Kang-MoonLee, Bo InLee, Sun-YoungLee, Chang KyunIm, Jong PilJang, Byung IkJeon, Tae JooCho, Yu KyungChang, Sae KyungJeon, Seong RanJung, Sung-AeJeen, Yoon TaeCha, Jae MyungHan, Dong SooKim, Won Ho
Issue Date
Nov-2016
Publisher
YONSEI UNIV COLL MEDICINE
Keywords
Crohn' s disease; infliximab; tuberculosis
Citation
YONSEI MEDICAL JOURNAL, v.57, no.6, pp.1376 - 1385
Indexed
SCIE
SCOPUS
KCI
Journal Title
YONSEI MEDICAL JOURNAL
Volume
57
Number
6
Start Page
1376
End Page
1385
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/5870
DOI
10.3349/ymj.2016.57.6.1376
ISSN
0513-5796
Abstract
Purpose: Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated. Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis. Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jeen, Yoon Tae photo

Jeen, Yoon Tae
Anam Hospital (Department of Gastroenterology and Hepatology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE